Department of Diagnostic Imaging & Nuclear Medicine, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
J Nucl Cardiol. 2023 Jun;30(3):1065-1074. doi: 10.1007/s12350-022-03106-1. Epub 2022 Oct 3.
We aimed to investigate the pre-treatment characteristics and treatment responses of isolated and systemic cardiac sarcoidosis (ICS and SCS) from FDG-PET/CT studies and to compare the prognoses of the two groups.
FDG-PET/CT images taken before and after treatment of 31 ICS and 91 SCS patients were analyzed retrospectively. Treatment response and recurrence were determined from the course of FDG-PET/CT. Treatment response and the incidence of both recurrence and major adverse cardiac events (MACE) were assessed in 16 ICS and 35 SCS patients who had been treated for more than 2 years.
A focal uptake pattern was more often observed than a focal-on-diffuse uptake pattern in both the ICS (74.2%) and SCS (63.7%) groups. Right ventricular involvement was significantly more frequent in SCS than ICS (44.0% vs. 9.6%, p < .001). SUVmax, cardiac metabolic volume (CMV), and cardiac metabolic activity (CMA) were significantly higher in SCS than ICS (SUVmax, 9.1 ± 4.1 vs. 4.8 ± 2.1; CMV, 118.0 ± 111.3 ml vs. 68.3 ± 94.7 ml; CMA, 541.6 ± 578.7 MBq vs. 265.1 ± 396.0 MBq, p < .001). Treatment responses in the two groups were similar, and complete resolution of cardiac uptake after immunosuppressive treatment was obtained in 62.5% of ICS patients and 77.1% of SCS patients (not significantly different). Likewise, no significant difference was found in the incidence of recurrence (40.0% for ICS, 44.4% for SCS) or MACE (25.0% for ICS, 22.8% for SCS).
SCS patients had more active and extensive CS lesions than ICS patients before treatment, but the two groups showed similar treatment responses and prognoses.
本研究旨在通过氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)研究,探讨孤立性和系统性心脏结节病(ICS 和 SCS)患者的治疗前特征和治疗反应,并比较两组患者的预后。
回顾性分析了 31 例 ICS 和 91 例 SCS 患者治疗前后的 FDG-PET/CT 图像。通过 FDG-PET/CT 随访确定治疗反应和复发情况。对 16 例 ICS 和 35 例 SCS 患者(治疗时间均超过 2 年)进行治疗反应评估,随访其复发和主要不良心脏事件(MACE)的发生率。
ICS 组(74.2%)和 SCS 组(63.7%)中均更常观察到局灶摄取模式而非局灶-弥漫摄取模式。SCS 组右心室受累的发生率明显高于 ICS 组(44.0%比 9.6%,p<0.001)。SCS 组的 SUVmax、心脏代谢容积(CMV)和心脏代谢活性(CMA)均明显高于 ICS 组(SUVmax,9.1±4.1 比 4.8±2.1;CMV,118.0±111.3 ml 比 68.3±94.7 ml;CMA,541.6±578.7 MBq 比 265.1±396.0 MBq,p<0.001)。两组的治疗反应相似,免疫抑制治疗后 ICS 患者中有 62.5%、SCS 患者中有 77.1%完全缓解心脏摄取。同样,两组的复发率(ICS 组为 40.0%,SCS 组为 44.4%)或 MACE(ICS 组为 25.0%,SCS 组为 22.8%)也无显著差异。
与 ICS 患者相比,SCS 患者治疗前的 CS 病变更活跃、更广泛,但两组的治疗反应和预后相似。